FATE News and Press, Fate Therapeutics Inc. From 12/07/20

Gainers: Obalon Therapeutics (OBLN) +121%.Greenland Technologies (GTEC) +79%.Oncternal Therapeutics (ONCT) +61%.Eastman Kodak (KODK) +60%.Fate Therapeutics (FATE) +46%.Nkarta (NKTX) +44%.Constellation Pharmaceuticals (CNST) +34%.Gamida Cell (GMDA) +31%.EHang Holdings (EH) +30%.Tonix...

Shares of Fate Therapeutics (NASDAQ: FATE) were skyrocketing 47.3% higher as of 11:43 a.m. EST on Monday. The huge jump came after the biotech announced positive interim data from an early-stage study of experimental cancer immunotherapy FT516 on Friday. Fate followed up with a pres...

Gainers: Obalon Therapeutics (OBLN) +116%, Oncternal Therapeutics (ONCT) +77%, Fate Therapeutics (FATE) +41%, Constellation Pharmaceuticals (CNST) +33%, Nkarta (NKTX) +28%.Losers: scPharmaceuticals (SCPH) -33%, Aptose Biosciences (APTO) -...

Fate Therapeutics (FATE) trades higher after a presentation over the weekend at the ASH conference on FT516 data. "Given the heavily pretreated nature of these patients, we believe FT516 played a dominant role in the combination’s activity, further de-risking iNK cells as a therapeutic...

Off-the-Shelf, iPSC-derived CAR NK Cell Product Candidate Drives Partial Response at First Dose Level of 30 Million Cells Deepening of Response Observed with FT596 Retreatment Duration of Response Comparable to FDA-approved Autologous CAR T-cell Therapy for Patients wi...

Gainers: [[OBLN]] +81%. [[MRIN]] +9.8%. [[FATE]] +8.8%. [[CRNX]] +6.7%. [[PROG]] +6.1%.Losers: [[HX]] -6.2%. [[INN]] -6.2%. [[RIDE]] -5.6%. [[MBIO]] -4.4%. [[EVK]] -3.8%. For further details see: RIDE, FATE, MBIO and MRIN among after-hours movers

Fate Therapeutics (FATE) rises 7% after hours, after announcing interim data from dose escalation Phase 1 study evaluating FT516 in combination with rituximab (Roche's Rituxan)for relapsed/ refractory B-cell lymphoma.FT516 is an off-the-shelf NK cell product candidate engineere...

3 of 4 Patients Evaluable for Efficacy in Dose Escalation Cohorts 2 and 3 Show Objective Response, with 2 Patients Achieving Complete Response No Observed Events of Any Grade of Cytokine Release Syndrome, Immune Effector Cell-Associated Neurotoxicity Syndrome, or Graft-vs-Ho...

SAN DIEGO, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced that management will host a virtual event enti...

SAN DIEGO, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced its participation in the following upcoming in...